This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
== Microbiology == The environment of the gingival sulcus is unlike any other location within the mouth. The ecosystem of the gingival sulcus is more anaerobic, and the site is filled with Gingival Crevicular Fluid (GCF). In the presence of periodontal disease, the gingival sulcus becomes a periodontal pocket and the oxidation reduction potential will decrease to low levels as the site is very anaerobic. At the same time, the gingival crevicular fluid would have increased by 147% when gingivitis is present and would have increased by up to 30-fold where periodontitis is present. While gingival crevicular fluid provides for the cellular defence and humoral factors to combat against the microbial insult, the gingival crevicular fluid also deliver novel substrates, in the form of proteins and glycoproteins, for bacterial metabolism. These include haeme containing molecules and iron, such as haemoglobin and transferrin. Dissimilarly to dental caries, many bacteria associated to periodontal disease cannot metabolise carbohydrates for energy (they are asaccharolytic) and are proteolytic too. One effect of proteolysis is that the pH of the gingival pocket with periodontal disease will increase and becomes slightly alkaline at around a pH level of 7.4 – 7.8 as compared to relatively neutral pH values, around a pH level of 6.9, when the gingival is healthy. In alkaline growth conditions, the enzyme activity and growth activity of periodontal pathogens, like Porphyromonas gingivalis.
These cleaning methods may include soaking powdered biomineral samples in bleach prior to extracting amino acids, destroying the amino acids in the more porous, open areas while leaving the fraction trapped inside the grains unscathed.
== Absorption, metabolism and excretion == Vitamin B6 is absorbed in the jejunum of the small intestine by passive diffusion. Even extremely large amounts are well absorbed. Absorption of the phosphate forms involves their dephosphorylation catalyzed by the enzyme alkaline phosphatase. Most of the vitamin is taken up by the liver. There, the dephosphorylated vitamins are converted to the phosphorylated PLP, PNP and PMP, with the two latter converted to PLP. In the liver, PLP is bound to proteins, primarily albumin. The PLP-albumin complex is what is released by the liver to circulate in plasma. Protein-binding capacity is the limiting factor for vitamin storage. Total body stores, the majority in muscle, with a lesser amount in liver, have been estimated to be in the range of 61 to 167 mg. Enzymatic processes utilize PLP as a phosphate-donating cofactor. PLP is restored via a salvage pathway that requires three key enzymes, pyridoxal kinase, pyridoxine 5'-phosphate oxidase, and phosphatases. Inborn errors in the salvage enzymes are known to cause inadequate levels of PLP in the cell, particularly in neuronal cells. The resulting PLP deficiency is known to cause or implicated in several pathologies, most notably infant epileptic seizures. The half-life of vitamin B6 varies according to different sources: one source suggests that the half-life of pyridoxine is up to 20 days, while another source indicates half-life of vitamin B6 is in range of 25 to 33 days.
== History == In 2005, the Siuzdak Lab created an open-source tool named XCMS in the programming language R. Noticing the need for a more accessible, graphical data processing tool they created the cloud-based XCMS Online in 2012. The ability for users to stream data directly from instruments while being acquired was added in 2014. Also in that year a commercial version named XCMS Plus (owned by Mass Consortium Corporation) was released and, in 2015, SCIEX became a reseller. In 2017 it was shown that XCMS Online could be used in a systems biology workflow. One year later, in the absence of a publicly available alternative, a version of XCMS Online and METLIN-MRM was released with the ability to perform multiple reaction monitoring (MRM) and generate MRMs. In 2026, a new version of METLIN-MRM was introduced that enabled a more refined means of generating MRM isotope removal, in-source fragment removal and spline-fitting at multiple collision energies. The accuracy of uMRM was demonstrated on over 300 molecular standards as compared to traditional approaches.
Sources: en.wikipedia.org
Choi has formed a militant band consisting of former police officers who were expelled or faked their own deaths, who had helped Lee take the fall for an operation he led in 1995. He promises Lee not only the position of commissioner, but also of security secretary later on, upon which Lee gives into temptation and help his son. Despite this, Lee tries to convince Joe to leave Choi's team for his safety. Legislator Oswald Kan is convinced by his old friend and junior Edward Lai, the current secretary of justice, to participate in the public inquiry into Lau. He chastises Lau for his methods of "desperate times, desperate measures" and disagrees with the "Cold War" operation being a successful failure. During another hearing, Kan is taken aback when Lee openly criticizes Lau, rather than defending him initially. Kan and Lau deduce that Lee is being controlled, as Kan tells his one of his pupils, Bella Au, to investigate. Lau also asks Cheung and his independent team to monitor both Lee and Kan, who he finds suspicious as Kan did not sign up for the public hearing until deadline and likely changed his mind. Au decides to secretly follow Lee, and later Choi whom Lee confers with. Realizing that they are being followed in a tunnel, Choi orders his subordinate to crash into Au's car, causing a chain collision in which Au is killed, and Choi's car is trapped. Lau arrives to investigate, and a shoot-out occurs, in which Joe is shot and severely injured by Lau, but Choi escapes. Lee accosts Lau for failing to keep his promise of Joe's safety and nearly fight before Kan interferes.
== Preptin == Preptin, a 34-aa peptide hormone produced by the pancreas, kidneys, breast tissues, and salivary glands, is derived from proteolytic cleavage of IGF-2 proprotein. The sequence of preptin (amino acids 93-126 of canonical IGF-2 preproprotein) is flanked by an N-terminal arginine (Arg) cleavage site and a C-terminal putative dibasic (Arg-Arg) cleavage motif. Preptin is present in islet beta-cells, undergoes glucose-mediated co-secretion with insulin, and acts as a physiological amplifier of glucose-mediated insulin secretion. It has an anabolic impact on bone growth and exhibits osteogenic properties, increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3. This activity resides within the first 16 amino acids of preptin. Genetic ablation of the preptin-coding region of Igf2 in female mice impairs pancreatic function.
Despite his turbulent criminal history, Olofsson pursued education, studying journalism while incarcerated. Released in 1983, he left Sweden with his wife, settling in Belgium. However, his criminal activities persisted, resulting in a drug smuggling conviction in 1999. The subsequent decades saw Olofsson's involvement in various criminal enterprises, leading to multiple arrests, imprisonments, and deportation. His life story, filled with escapes, convictions, and legal battles, became the subject of films, documentaries, and a Netflix drama series in 2022.
=== Moisture balance === Establishing a moisture balance beneficial to the wound bed is another prerequisite of care. The natural response to injury is inflammation typified by the local expression of histamine and bradykinin and leading to vasodilation of the vessels that are in relative close proximity to the site of injury. As serum based fluid moves out of the vessels into the interstitial spaces the resultant soft tissue oedema manifests on the wound surface as exudate. In the chronic wound this exudate contains a surfeit of proteolytic enzymes and other components not seen in acute wounds and these compounds have a corrosive effect on the wound bed and surrounding peri-wound skin. The application of dressings, topical negative pressure, compression garments and leg elevation/exercise have been identified as methods for management of wound exudate.
Mr. Mike's SteakhouseCasual is a chain of restaurants in Western Canada. It began as a steakhouse where the most popular item on the menu was the Mikeburger, which consisted of grilled steak served on a fresh French loaf with garlic butter and the secret Mike Sauce. It has since evolved to a casual dining arrangement with a "West Coast feel". Mr. Mike's now features a broad menu and full liquor licence, and targets a different demographic. Their first restaurant in Eastern Canada opened in Welland Ontario on November 21, 2017.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。